Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGER | Q15109 | 3/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.42 |
| ▸ | DCUN1D1 | Q96GG9 | 5/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | UBE2M | P61081 | 3/20 | 0.39 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.39 |
| ▸ | CTSD | P07339 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1460744 | 0.90 | DPP4 (0.48) | AGERMTNR1AOPRM1DCUN1D1CHRM2 | |
| SCHEMBL1460997 | 0.86 | OPRM1 (0.55) | AGERMTNR1AOPRM1DCUN1D1 | |
| SCHEMBL1461928 | 0.85 | OPRM1 (0.58) | AGERMTNR1AOPRM1TMEM97 | |
| SCHEMBL15521608 | 0.80 | DCUN1D1 (0.60) | AGERMTNR1AOPRM1DCUN1D1CTSD | |
| SCHEMBL1461003 | 0.78 | SLC6A2 (0.41) | OPRM1CHRM2CHRM3CTSD | |
| SCHEMBL6031045 | 0.77 | AGER (0.43) | AGERMTNR1AOPRM1DCUN1D1CHRM2 | |
| SCHEMBL1461945 | 0.76 | GRIN2B (0.48) | DPP4DPP9DPP7 | |
| SCHEMBL3885750 | 0.76 | OPRM1 (0.41) | AGERMTNR1AOPRM1DCUN1D1CHRM2 | |
| SCHEMBL3885752 | 0.76 | OPRM1 (0.41) | AGERMTNR1AOPRM1DCUN1D1CHRM2 | |
| SCHEMBL5355490 | 0.75 | SLC6A2 (0.44) | OPRM1DPP4DPP9DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4644714-B2 | — | — | 2011-03-02 | — | — | JP | claimed |
| JP-2008524280-A | — | — | 2008-07-10 | — | — | JP | claimed |
| EP-1831158-A1 | NOVEL CYCLOHEXANE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2007-09-12 | — | — | EP | claimed |
| US-7253282-B2 | Hexafluoroisopropanol substituted cyclohexane derivatives | HOFFMAN-LA ROCHE INC. (US) | 2007-08-07 | — | — | US | claimed |
| WO-2006066779-A1 | NOVEL CYCLOHEXANE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2006-06-29 | — | — | WO | claimed |
| US-20060135601-A1 | Novel hexafluoroisopropanol substituted cyclohexane derivatives | HOFFMANN-LA ROCHE INC. | 2006-06-22 | — | — | US | claimed |
| US-7253282-B2 | Hexafluoroisopropanol substituted cyclohexane derivatives | HOFFMAN-LA ROCHE INC. (US) | 2007-08-07 | — | — | US | disclosed |
| US-20060135601-A1 | Novel hexafluoroisopropanol substituted cyclohexane derivatives | HOFFMANN-LA ROCHE INC. | 2006-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135601-A1 | Novel hexafluoroisopropanol substituted cyclohexane derivatives | NR1H3, NR1H2, NR1I2 | AGER 2121/4885MTNR1A 677/4885OPRM1 216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.